Biomedical Engineering Reference
In-Depth Information
FURTHER READINGS
Acharya, K.R. and Lloyd, M.D. 2005. The advantages and limitations of protein crystal structures.
Trends
Pharmacol. Sci
. 26:10-14.
Brange, J. et al. 1988. Monomeric insulins obtained by protein engineering and their medical implications.
Nature
333:679-682.
Davis, A.M. et al. 2003. Applications and limitations of x-ray crystallographic data in structure-based ligand
and drug design.
Angew. Chem. Int. Ed
. 42:2718-2736.
Hansen, K.B. et al. 2007. Structural aspects of AMPA receptor activation, desensitization and deactivation.
Curr. Oprin. Neurobiol
. 17:281-288.
Hardy, L.W. and Malikayil, A. 2003. The impact of structure-guided drug design on clinical agents.
Curr. Drug
Discov
. 3:15-20.
Lam, P.Y.S. et al. 1994. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibi-
tors.
Science
263:380-384.
McCusker, E.C. et al. 2007. Heterologous GPCR expression: A bottleneck to obtaining crystal structures.
Biotechnol. Prog
. 23:540-547.
Russell, R.J. et al. 2006. The structure of H5N1 avian inl uenza neuraminidase suggests new opportunities for
drug design.
Nature
443:45-49.
Thornton, J.M. et al. 2000. From structure to function: Approaches and limitations.
Nat. Struct. Biol
.
7:991-994.
von Itzstein, M. et al. 1993. Rational design of potent sialidase-based inhibitors of inl uenza virus replication.
Nature
363:418-423.
